News
16 May 2017
Friulchem S.p.A. Issued Patent for Rifaximin
Friulchem S.p.A., a chemical-pharmaceutical company
active in human and veterinary fields, has received an US Patent (US Patent
14/11856) covering own solid form called “pseudo-crystalline” solid form,
derived from Rifamycin O.
Rifaximin is approved for the treatment of travelers'
diarrhea in adults and in children 12-years of age and older. Rifaximin has
also been evaluated for the treatment of hepatic encephalopathy, infectious
diarrhea, diverticular disease and as an antibacterial prophylactic prior to
colon surgery.
Friulchem and its partners started the development of finished product both in human and veterinary fields.
Under granting there are also EU patent n. 12721559.8 and MX patent n. MX/A/2013/013463.
Mentioned Companies
FRIULCHEM S.P.A.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance